Technical Analysis for INSYQ - Insys Therapeutics Inc
ADX | Long-Term | Intermediate-Term | Short-Term |
---|---|---|---|
Weak or Absent | N/A | Down | Up |
See historical INSYQ trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
20 DMA Resistance | Bearish | 12.28% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 12.28% | |
Stochastic Reached Oversold | Weakness | 12.28% | |
Wide Bands | Range Expansion | 12.28% | |
Oversold Stochastic | Weakness | 12.28% | |
20 DMA Resistance | Bearish | -13.47% | |
Pocket Pivot | Bullish Swing Setup | -13.47% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Sector: Healthcare
- Industry: Biotechnology
Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. On June 10, 2019, INSYS Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
RTT Euphoriants Drugs Pharmaceutical Pain Organic Compounds U.S. Bankruptcy Court Chemotherapy Drug Delivery U.S. Bankruptcy Court For The District Of Delaware Analgesics Morphinans Opioids Vomiting Drug Delivery Systems Glioblastoma Multiforme Aids Chemotherapy Induced Nausea Fentanyl Allergic Reactions Dronabinol
RTT Euphoriants Drugs Pharmaceutical Pain Organic Compounds U.S. Bankruptcy Court Chemotherapy Drug Delivery U.S. Bankruptcy Court For The District Of Delaware Analgesics Morphinans Opioids Vomiting Drug Delivery Systems Glioblastoma Multiforme Aids Chemotherapy Induced Nausea Fentanyl Allergic Reactions Dronabinol
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Date | Title |
---|
Indicator | Value |
---|---|
52 Week High | 0.344 |
52 Week Low | 0.03 |
Average Volume | 147,160 |
200-Day Moving Average | 0.0000 |
50-Day Moving Average | 0.1001 |
20-Day Moving Average | 0.0712 |
10-Day Moving Average | 0.0641 |
Average True Range | 0.0207 |
ADX | 8.83 |
+DI | 17.2260 |
-DI | 16.3356 |
Chandelier Exit (Long, 3 ATRs ) | 0.0604 |
Chandelier Exit (Short, 3 ATRs ) | 0.1141 |
Upper Bollinger Band | 0.0918 |
Lower Bollinger Band | 0.0506 |
Percent B (%b) | 0.35 |
BandWidth | 57.8652 |
MACD Line | -0.0110 |
MACD Signal Line | -0.0121 |
MACD Histogram | 0.0011 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.0997 | ||||
Resistance 3 (R3) | 0.0993 | 0.0872 | 0.0939 | ||
Resistance 2 (R2) | 0.0872 | 0.0784 | 0.0875 | 0.0920 | |
Resistance 1 (R1) | 0.0761 | 0.0729 | 0.0817 | 0.0765 | 0.0900 |
Pivot Point | 0.0640 | 0.0640 | 0.0668 | 0.0643 | 0.0640 |
Support 1 (S1) | 0.0529 | 0.0552 | 0.0585 | 0.0533 | 0.0398 |
Support 2 (S2) | 0.0408 | 0.0497 | 0.0411 | 0.0378 | |
Support 3 (S3) | 0.0297 | 0.0408 | 0.0359 | ||
Support 4 (S4) | 0.0301 |